A Quick Metric for Measuring Pharma's Success in Healthcare Reform
This article was originally published in RPM Report
Executive Summary
Pharma is looking at some very achievable business targets from the pending health care reform legislation. It’s not going to take too many new scripts from the people who currently do not have insurance for pharma to get a return from the new tax and rebate payments that are part of its support for ObamaCare.
You may also be interested in...
Medicaid Expansion: Glass Half Full for Biopharma
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.
Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
The Supreme Court and Biosimilars: What if it All Goes Away?
After the bruising health care reform debate in Congress, biopharmaceutical companies were comfortably on the periphery of the legal arguments playing out in the Supreme Court. But being peripheral has its disadvantages: if the Court sides with the challengers, it is possible that one of the “peripheral” provisions tossed aside will be the new biosimilars pathway. That would be a disaster for innovator companies.